N🧠Brains, Bots, and FDA-Approved Hope
What Icobrain Means for Alzheimer’s — and What Still Needs Building
Last month, the FDA approved something that should’ve made a bigger splash: Icobrain ARIA — the first-ever AI tool cleared to detect and measure amyloid-related imaging abnormalities (ARIA) on MRI scans in Alzheimer’s patients.
In plain English?
It helps doctors spot side effects from new Alzheimer’s drugs — like Donanemab (Kisunla) — earlier and more precisely. That’s good news, especially when “missing something on a scan” can mean swelling or microbleeds in the brain.
So yes — this is a big deal. AI helping radiologists = progress.
But let’s be clear:
It still won’t help you remember your meds.
It won’t get you dressed.
It won’t restore your routine, your identity, or your joy.
That’s where MiM comes in.
🧠We Need Medical Tools — and Life Tools
Icobrain ARIA is a powerful advancement in diagnostics. But we also need something that supports the rest of the day — the “What do I do now?” part.
That’s what we’re building with MiM.
MiM is a support platform for people in the early stages of Alzheimer’s — and for the loved ones walking beside them. It’s not another reminder app. It’s a structure for living well, even when memory starts to shift.
Because you can’t MRI your way through breakfast.
✨ Want to See It in Action?
We're building it now. And it’s already helping people — including my husband Tim — live with more purpose and less fear.
đź’¬ Visit LiveWithMiM.org
📬 Or read Letters from Tim — his journey, in his own words.
We can’t slow the disease — yet.
But we can preserve structure, dignity, and meaning.
That’s what MiM is here for.
—
Vanessa Saunders (Grandma)
Founder, MiM
https://mimconnect.substack.com